FIGURE 8.

Effect of DUSP1 targeting siRNA on IL1B-induced inflammatory gene protein release/expression. A, A549 cells were incubated with LMNA (control) or DUSP1-specific siRNAs for 24 h before being treated with IL1B (1 ng/ml) or IL1B plus dexamethasone (1 μm) (Dex) as indicated. Supernatants were harvested after 2 or 6 h for cytokine/chemokine release measurement. Data (n = 9–15) expressed as picograms/ml are plotted as mean ± S.E. Note: release of CSF2 at 2 h was below the detection limit of the assay. Significance was tested between the LMNA control siRNA plus IL1B and each of the DUSP1 targeting siRNAs plus IL1B, and LMNA control plus IL1B plus Dex using ANOVA with a Newman-Keul multiple comparison test. Other comparisons are specifically indicated. *, p < 0.05; **, p < 0.01; ***, p < 0.001. B, for each cytokine/chemokine at each time, the effect of IL1B plus Dex was expressed as a percentage of IL1B for each of the three individual siRNAs and is plotted as a mean ± S.E. The percent of IL1B plus dexamethasone/IL1B for the LMNA siRNA is compared with that for each DUSP1-specific siRNAs using ANOVA with a Dunnett's post-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. C, Cells were treated as in A and harvested for Western blot analysis of PTGS2 and GAPDH. Blots representative of at least 4 such experiments are shown.